Discovery of a Potent and Selective Cell‐Active Inhibitor of Histidine‐N1 Methyltransferase METTL9
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.3642560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Rui Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Methyltransferases, Enzyme Inhibitors, Histidine, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Protein histidine N1‐methylation (1‐methylhistidine, 1‐MH) is a prevalent yet underexplored post‐translational modification in mammals. The methyltransferase METTL9 acts as an important enzyme catalyzing 1‐MH of histidine in diverse protein substrates, with mounting evidence suggesting its involvement in tumor progression. Despite its potential significance, no inhibitors targeting METTL9 have been previously identified. Here, we introduce compound METTL9i as a first‐in‐class, highly potent, and selective METTL9 inhibitor. METTL9i inhibits METTL9 with a half‐maximum inhibitory concentration (IC 50 ) of 0.067 ± 0.009 µM and exhibits selectivity over other methyltransferases. Structural analysis via crystallography reveals that METTL9i binds within the S‐adenosylmethionine (SAM) binding pocket. In cells, METTL9i engages METTL9 and leads to a reduction in global 1‐MH levels. These results support METTL9i as a useful tool compound for investigating METTL9 biology and the functions of histidine 1‐MH, while also serving as a promising lead compound for drug discovery targeting METTL9.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- New Cornerstone Science Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
- New Cornerstone Science Foundation
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- Sichuan Science and Technology Program
- National Key Research and Development Program of China
Zitieren
APA
Yao, R., Zhang, G., Huang, Y., Fan, D., Zhang, H., Qiao, J., Chen, C., Shao, Z., Li, L., & Yang, S. (2026). Discovery of a Potent and Selective Cell‐Active Inhibitor of Histidine‐N1 Methyltransferase METTL9. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.3642560
Vancouver
Yao R, Zhang G, Huang Y, Fan D, Zhang H, Qiao J, et al. Discovery of a Potent and Selective Cell‐Active Inhibitor of Histidine‐N1 Methyltransferase METTL9. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.3642560
BibTeX
@article{Yao2026,
author = {Yao, Rui and Zhang, Guo and Huang, Yuanting and Fan, Danchen and Zhang, Hailin and Qiao, Jingxin and Chen, Chong and Shao, Zhenhua and Li, Linli and Yang, Shengyong},
title = {Discovery of a Potent and Selective Cell‐Active Inhibitor of Histidine‐N1 Methyltransferase METTL9},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.3642560}
}
EUVIMED